OBJECTIVE

To assess the effectiveness of capmatinib therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with METex14 mutation for subsequent cost-effectiveness analysis.

MATERIAL AND METHODS

Clinical situation was limited to first-line therapy. An alternative to targeted therapy with capmatinib In Russian practice is non-targeted chemotherapy (CT) or immunotherapy (IT). Systematic analysis of available studies devoted to therapy in patients with NSCLC and METex14 necessitated indirect comparison. After comparing the population characteristics in the studies selected for naive indirect comparison, we performed statistical analysis of progression-free survival (PFS) for capmatinib therapy and non-targeted therapy (CT or IT).

RESULTS

There were no significant differences in characteristics of populations with METex14 NSCLC in the study of first-line capmatinib and non-targeted therapy (CT or IT alone). Capmatinib therapy had significant benefit in PFS (p log-rank =0.009). The hazard ratio for PFS in capmatinib therapy compared to non-targeted therapy was 0.485 (95% CI 0.280—0.840).

CONCLUSION

PFS in drug-naive patients with locally advanced or metastatic METex14 NSCLC was significantly higher after capmatinib compared to non-targeted therapy (chemotherapy or immunotherapy alone).